MLH1 and cancer: We identified twice as many genetic syndromes (44.9%) in the unusual MMR-D population as in the classical MMR-D population (21.4%) despite the high volume of CRC in our cohort, which classically contain a high proportion of sporadic MMR-D cancers due to hypermethylation of the MLH1 promotor.